IL260024B - Method for assessing the response to pd-1/pdl-1 targeting drugs - Google Patents
Method for assessing the response to pd-1/pdl-1 targeting drugsInfo
- Publication number
- IL260024B IL260024B IL260024A IL26002418A IL260024B IL 260024 B IL260024 B IL 260024B IL 260024 A IL260024 A IL 260024A IL 26002418 A IL26002418 A IL 26002418A IL 260024 B IL260024 B IL 260024B
- Authority
- IL
- Israel
- Prior art keywords
- pdl
- drug therapy
- targeted drug
- evaluating response
- evaluating
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307050 | 2015-12-18 | ||
| PCT/EP2016/081485 WO2017103147A1 (en) | 2015-12-18 | 2016-12-16 | Method for assessing the response to pd-1/pdl-1 targeting drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL260024A IL260024A (en) | 2018-07-31 |
| IL260024B true IL260024B (en) | 2021-07-29 |
Family
ID=55129471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260024A IL260024B (en) | 2015-12-18 | 2018-06-14 | Method for assessing the response to pd-1/pdl-1 targeting drugs |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11137404B2 (https=) |
| JP (1) | JP6762363B2 (https=) |
| KR (1) | KR102378298B1 (https=) |
| IL (1) | IL260024B (https=) |
| WO (1) | WO2017103147A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101980003B1 (ko) * | 2017-09-14 | 2019-05-17 | 건국대학교 글로컬산학협력단 | 면역체크포인트의 발현을 억제하기 위한 물질을 포함하는 나노입자 전달체 |
| KR102216725B1 (ko) * | 2017-12-29 | 2021-02-17 | 연세대학교 산학협력단 | 면역 항암 요법에 대한 치료 반응 예측 방법 |
| WO2019159825A1 (ja) * | 2018-02-14 | 2019-08-22 | 国立大学法人名古屋大学 | 抗pd-1抗体/抗pd-l1抗体療法の効果を予測するバイオマーカー |
| GB201805876D0 (en) * | 2018-04-09 | 2018-05-23 | Francis Crick Institute Ltd | Method |
| JP2022533012A (ja) * | 2019-04-30 | 2022-07-21 | エックスセル・バイオサイエンシズ・インコーポレイテッド | 細胞表現型を調節するための系および方法 |
| WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| KR20230125672A (ko) * | 2022-02-21 | 2023-08-29 | 사회복지법인 삼성생명공익재단 | 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
-
2016
- 2016-12-16 JP JP2018529539A patent/JP6762363B2/ja active Active
- 2016-12-16 US US16/061,667 patent/US11137404B2/en not_active Expired - Fee Related
- 2016-12-16 WO PCT/EP2016/081485 patent/WO2017103147A1/en not_active Ceased
- 2016-12-16 KR KR1020187020429A patent/KR102378298B1/ko active Active
-
2018
- 2018-06-14 IL IL260024A patent/IL260024B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6762363B2 (ja) | 2020-09-30 |
| US11137404B2 (en) | 2021-10-05 |
| KR20180115262A (ko) | 2018-10-22 |
| WO2017103147A1 (en) | 2017-06-22 |
| IL260024A (en) | 2018-07-31 |
| KR102378298B1 (ko) | 2022-03-23 |
| JP2019500870A (ja) | 2019-01-17 |
| US20180364241A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260024B (en) | Method for assessing the response to pd-1/pdl-1 targeting drugs | |
| IL283561B (en) | Methods for treating ocular diseases | |
| IL257091B (en) | Targeted oligonucleotides | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| EP3368656A4 (en) | TARGETED CANCER THERAPY | |
| IL257252A (en) | Methods of treating fgf21-associated disorders | |
| IL281293A (en) | Methods of treating hyperalgesia | |
| BR112017018054A2 (pt) | métodos para a cobertura de sequências de ácidos nucleicos direcionadas | |
| PL3978070T3 (pl) | Urządzenie magnetyczne do stymulacji terapeutycznej | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| EP3349677C0 (en) | ELECTROSURGICAL DEVICE | |
| HRP20190165T1 (hr) | Genska terapija za fabryjevu bolest | |
| DK3234134T3 (da) | Målrettet rna-redigering | |
| HUE051767T2 (hu) | Új eljárások oligonukleotidok elõállítására | |
| DK3153148T3 (da) | Apparat til seksuel stimulation | |
| DK3262066T4 (da) | Genterapi | |
| MA39483A (fr) | Agents thérapeutiques cibles | |
| EP3310303A4 (en) | TORSION STABILIZED ENDOPROSTHESIS DEVICE | |
| EP3333833A4 (en) | TECHNOLOGY SIMULATOR | |
| HUE049511T2 (hu) | Módszer magok stimulálására | |
| SI4119569T1 (sl) | Konjugirane protismiselne spojine za uporabo v terapiji | |
| DK3310432T3 (da) | Indretning til effektiv ikke-invasiv to-trinsneurostimulation | |
| DK3355890T3 (da) | Humane plasmakallikreininhibitorer | |
| IL253549B (en) | Antibody-urease conjugates for therapeutic purposes | |
| EP3309163A4 (en) | SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE |